Related Experiment Video
Updated: Nov 19, 2025
Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
UBE2R2-AS1 Inhibits Xenograft Growth in Nude Mice and Correlates with a Positive Prognosis in Glioma
Wu Xu1,2, Dan-Dan Che3, Liang Chen2
1Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Abstract:
Our previous study showed that the lncRNA UBE2R2-AS1 inhibits the growth and invasion of glioma cells and promotes apoptosis through the miR-877-3p/TLR4 pathway. In this study, it was further found that the expression of UBE2R2-AS1 in glioma tissues was decreased significantly, and gradually decreased with increasing clinical stage. Chi-square analysis showed that the expression of UBE2R2-AS1 was significantly correlated with the WHO stage of tumor and epilepsy. Using Kaplan-Meier univariate survival analysis, it was found that the expression of UBE2R2-AS1 correlated positively with the overall survival of patients with glioma, while multiple Cox regression analysis showed that the expression of UBE2R2-AS1 correlated positively with the overall survival of patients with glioma as a protective factor for glioma prognosis. The analysis of data from TCGA also showed that patients with high UBE2R2-AS1 levels or low miR-877-3p expression were more likely to have good survival outcomes. Further construction of a glioma xenograft model in nude mice showed that UBE2R2-AS1 overexpression inhibited the growth of tumors, and the inhibition of miR-877-3p expression had a similar effect. Simultaneous UBE2R2-AS1 overexpression and miR-877-3p inhibition further decreased the growth rate of tumors in nude mice. Taken together, the results of our study suggest that UBE2R2-AS1 is an important tumor suppressor gene in glioma, which may be a good marker and treatment target for the clinical detection of glioma.
Insights
Long non-coding RNA UBE2R2-AS1 acts as a tumor suppressor in glioma. Its decreased expression correlates with advanced stages and poor prognosis, suggesting it
Area of Science:
- * Molecular oncology
- * Cancer genetics
- * RNA biology
Background:
- * Glioma is a primary brain tumor with significant mortality.
- * Long non-coding RNAs (lncRNAs) play crucial roles in cancer development.
- * UBE2R2-AS1 was previously shown to inhibit glioma cell growth and invasion.
Purpose of the Study:
- * To investigate the expression and prognostic significance of UBE2R2-AS1 in glioma.
- * To explore the relationship between UBE2R2-AS1, miR-877-3p, and glioma progression.
- * To evaluate UBE2R2-AS1 as a potential therapeutic target for glioma.
Main Methods:
- * Analysis of UBE2R2-AS1 expression in glioma tissues and correlation with clinical parameters (WHO stage, epilepsy).
- * Kaplan-Meier survival analysis and Cox regression to assess prognostic value.
- * TCGA data analysis for UBE2R2-AS1 and miR-877-3p expression and survival outcomes.
- * Glioma xenograft mouse models to study the in vivo effects of UBE2R2-AS1 and miR-877-3p.
Main Results:
- * UBE2R2-AS1 expression was significantly decreased in glioma tissues, correlating with higher WHO stage.
- * Low UBE2R2-AS1 expression was associated with shorter overall survival in glioma patients.
- * UBE2R2-AS1 overexpression and miR-877-3p inhibition suppressed tumor growth in vivo.
- * High UBE2R2-AS1 or low miR-877-3p predicted better survival outcomes.
Conclusions:
- * UBE2R2-AS1 functions as a tumor suppressor gene in glioma.
- * UBE2R2-AS1 expression is a potential prognostic biomarker for glioma.
- * UBE2R2-AS1 represents a promising therapeutic target for glioma treatment.
